Amneal Pharmaceuticals warned consumers Monday of a defect in some of its epinephrine auto-injectors that could cause the devices to inject someone with a lethal amount of the allergy drug.
The Food and Drug Administration then alerted patients, caregivers, and health-care providers about the defect and instructed them to immediately inspect certain lots of the devices.
Sixty batches of auto-injectors were affected, according to Impax Laboratories, a subsidiary of Amneal. Consumers, pharmacists, and health-care providers who received a device after Dec. 20, 2018 should check to make sure their auto-injector has a yellow “stop collar,” which prevents the device from ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.